Table 1.

Descriptive data concerning survival (in days) as well as distribution of anti-p53 antibodies for investigated clinical parameters. The reported p-values relates to survival according to univariate analysis for the investigated clinical parameters

Variables	Number of patients	Median Surv (days)	SD*	Anti p53 abs Median/Range	P-value
Gender					0.75
Male	62	330	582	0.08 (0–140)
Female	22	363	257	0.1 (0–32)
Stage					0.63
3a	47	324	660	0.02 (0–140)
3b	25	332	203	0.23 (0–43)
4	12	383	226	0.04 (0–25)
Performance status					0.77
0	53	312	286	0.04 (0–43)
1	21	359	392	0.23 (0–140)
2	8	319	160	0.3 (0–32)
Smoking					0.29
Yes	53	387	339	0.05 (0–140)
Ex-smoker	22	294	228	0.24 (0–43)
No	5	290	158	0.12 (0–6)
Weight reduction. kg					0.78
Yes	42	348	293	0.20 (0–140)
No	21	281	317	0.0 (0–10)
Histology					0.73
Squamous carcinoma	59	324	321	0.08 (0–140)
Adenocarcinoma	23	347	839	0.12 (0–25)
Bronchioalv. ca	2	452	375	0.03 (0–0.05)
Tumour volume (recist)					0.007
<50	18	446	433	0.04 (0–6)
>50	21	290	142	0.22 (0–140)
Subjective improvement					0.95
Yes	41	306	333	0.12 (0–140)
No	11	306	146	0 (0–32)
Objective improvement					0.73
Stable disease	5	551	371		0.06 (0–13)
Regress of tumour	3	684	252	0 (0–0)
Progress of tumour	2	526	333	0.55 (0–1.1)
Anti-p53 antibodies					0.29
Continuous
Anti-p53 antibodies index					0.96
neg	68	334	543
intermediate	2	486	390
pos	14	330	410